Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 111-116

  Moore, Owen A ^a,b   Proudman, Susanna M ^c,d   Goh, Nicole ^e,f   Corte, Tamera J ^g   Rouse, Hannah ^a   Hennessy, Oliver ^a   Morrisroe, Kathleen ^a   Thakkar, Vivek ^a,h,i   Sahhar, Joanne ^j   Roddy, Janet ^k   Youssef, Peter ^g   Gabbay, Eli ^k,l   Nash, Peter ^m   Zochling, Jane ⁿ   Stevens, Wendy ^a   Nikpour, Mandana ^a,o  

^a ST VINCENT S HOSPITAL   (Australia)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e AUSTIN HOSPITAL   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h LIVERPOOL HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

^j MONASH MEDICAL CENTRE   (Australia)

^k ROYAL PERTH HOSPITAL   (Australia)

^l UNIVERSITY OF NOTRE DAME   (Australia)

^m UNIVERSITY OF QUEENSLAND   (Australia)

ⁿ UNIVERSITY OF TASMANIA   (Australia)

^o UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Interstitial lung disease; Prognosis; Pulmonary function; Scleroderma; Systemic sclerosis

Indexed keywords

ADULT; AGED; ALVEOLAR VOLUME RATIO; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE MARKER; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXYGEN THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; AREA UNDER THE CURVE; AUSTRALIA; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; LUNG; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC; TIME; VITAL CAPACITY;

AGED; AREA UNDER CURVE; AUSTRALIA; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; RESPIRATORY FUNCTION TESTS; ROC CURVE; SCLERODERMA, SYSTEMIC; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84946209246     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
2. BOUROS D, WELLS AU, NICHOLSON AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
3. STEEN V, CONTE C, OWENS G, MEDSGER TJ: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
4. MATHAI SC, HUMMERS LK, CHAMPION HC et al.: Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
5. STEELE R, HUDSON M, LO E, BARON M: Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-24.
6. SCHURAWITZKI H, STIGLBAUER R, GRANINGER W et al.: Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176: 755-9.
7. MOORE OA, GOH N, CORTE T et al.: Extent of disease on high-resolution computed tomo-graphy lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
8. GOH NS, DESAI SR, VEERARAGHAVAN S et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
9. STEEN V: Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-9.
10. KHANNA D, DENTON CP: Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387-400.
11. van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-55.
12. LeROY EC, MEDSGER TA, Jr.: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
13. LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
14. McDONALD CF, CROCKETT AJ, YOUNG IH: Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. Med J Aust 2005; 182: 621-6.
15. PLASTIRAS SC, KARADIMITRAKIS SP, ZIAKAS PD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOS HM, TZELEPIS GE: Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
16. KHANNA D, TSENG CH, FARMANI N et al.: Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078-85.
17. du BOIS RM, WEYCKER D, ALBERA C et al.: Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-9.
18. COLLARD HR, KING TE Jr., BARTELSON BB, VOURLEKIS JS, SCHWARZ MI, BROWN KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-42.
19. LATSI PI, du BOIS RM, NICHOLSON AG et al.: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-7.
20. RAGHU G, COLLARD HR, EGAN JJ et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
21. ZAPPALA CJ, LATSI PI, NICHOLSON AG et al.: Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-6.
22. RICHELDI L, RYERSON CJ, LEE JS et al.: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-11.